Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
• Walhalla Gold names VP of exploration to lead Victorian portfolio